Bristol Myers Squibb Company $BMY Holdings Raised by First National Trust Co

First National Trust Co lifted its stake in Bristol Myers Squibb Company (NYSE:BMY) by 41.6% in the third quarter, HoldingsChannel reports. The firm owned 53,564 shares of the biopharmaceutical company’s stock after purchasing an additional 15,742 shares during the period. First National Trust Co’s holdings in Bristol Myers Squibb were worth $2,416,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. CVA Family Office LLC increased its position in shares of Bristol Myers Squibb by 2.6% in the third quarter. CVA Family Office LLC now owns 8,959 shares of the biopharmaceutical company’s stock worth $404,000 after acquiring an additional 223 shares in the last quarter. Mccarter Private Wealth Services LLC grew its position in Bristol Myers Squibb by 5.0% during the 3rd quarter. Mccarter Private Wealth Services LLC now owns 4,931 shares of the biopharmaceutical company’s stock worth $222,000 after purchasing an additional 235 shares in the last quarter. Creative Financial Designs Inc. ADV raised its stake in Bristol Myers Squibb by 26.7% during the 2nd quarter. Creative Financial Designs Inc. ADV now owns 1,123 shares of the biopharmaceutical company’s stock valued at $52,000 after purchasing an additional 237 shares during the period. Center for Financial Planning Inc. lifted its holdings in shares of Bristol Myers Squibb by 15.9% in the second quarter. Center for Financial Planning Inc. now owns 1,869 shares of the biopharmaceutical company’s stock valued at $87,000 after purchasing an additional 256 shares in the last quarter. Finally, Tilson Financial Group Inc. boosted its position in shares of Bristol Myers Squibb by 4.2% in the third quarter. Tilson Financial Group Inc. now owns 6,445 shares of the biopharmaceutical company’s stock worth $291,000 after buying an additional 259 shares during the period. Institutional investors and hedge funds own 76.41% of the company’s stock.

Bristol Myers Squibb Stock Up 0.1%

Bristol Myers Squibb stock opened at $60.82 on Wednesday. The company has a current ratio of 1.27, a quick ratio of 1.17 and a debt-to-equity ratio of 2.39. Bristol Myers Squibb Company has a 1-year low of $42.52 and a 1-year high of $63.33. The firm’s fifty day simple moving average is $54.82 and its 200-day simple moving average is $49.20. The company has a market capitalization of $123.81 billion, a P/E ratio of 17.63, a P/E/G ratio of 0.17 and a beta of 0.29.

Bristol Myers Squibb (NYSE:BMY) last posted its earnings results on Thursday, February 5th. The biopharmaceutical company reported $1.26 EPS for the quarter, missing the consensus estimate of $1.65 by ($0.39). Bristol Myers Squibb had a return on equity of 70.30% and a net margin of 14.64%.The business had revenue of $12.50 billion for the quarter, compared to analyst estimates of $12.24 billion. During the same period in the previous year, the company earned $1.67 earnings per share. The company’s quarterly revenue was up 1.3% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. Sell-side analysts forecast that Bristol Myers Squibb Company will post 6.74 earnings per share for the current fiscal year.

Bristol Myers Squibb Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, February 2nd. Investors of record on Friday, January 2nd were paid a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a dividend yield of 4.1%. The ex-dividend date of this dividend was Friday, January 2nd. This is a positive change from Bristol Myers Squibb’s previous quarterly dividend of $0.62. Bristol Myers Squibb’s dividend payout ratio (DPR) is 73.04%.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on the company. Wells Fargo & Company reissued an “outperform” rating and set a $60.00 price target (up from $55.00) on shares of Bristol Myers Squibb in a research report on Friday. Sanford C. Bernstein reiterated a “market perform” rating on shares of Bristol Myers Squibb in a report on Monday, November 3rd. Morgan Stanley reissued an “underweight” rating and issued a $40.00 price target on shares of Bristol Myers Squibb in a research report on Friday. UBS Group raised shares of Bristol Myers Squibb from a “neutral” rating to a “buy” rating and boosted their price objective for the company from $46.00 to $65.00 in a research report on Wednesday, January 7th. Finally, The Goldman Sachs Group reiterated a “neutral” rating and issued a $57.00 target price (up previously from $51.00) on shares of Bristol Myers Squibb in a research report on Tuesday, December 2nd. Eight equities research analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $59.20.

Bristol Myers Squibb Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.